Rigel Pharma (RIGL) Tops Q4 EPS by 1c

Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Simply Good Foods (SMPL) Tops Q3 EPS by 7c; offers outlook
• Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
• Bloom Energy rejects short-seller report on finances and supply chain